China Pharma Holdings, Inc. (NYSE:CPHI) tinted loss of 0% (0 points) to US$0.27. The volume of 0.14 Million shares climbed down over an trading activity of 496.37 Million shares. EPS ratio determined by looking at last 12 month figures is -0.44. Over the same time span, the stock marked US$1.45 as its best level and the lowest price reached was US$0.15. The corporation has a market cap of US$12.02 Million.

China Pharma Holdings, Inc. (NYSE:CPHI)’s earnings per share has been growing at a -43.9 percent rate over the past 5 year when average revenue increase was noted as -24.7 percent. The return on equity ratio or ROE stands at -35.8 percent while most common profitability ratio return on investment (ROI) was -35.5 percent. The company’s institutional ownership is monitored at 5.9 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 18.7 percent gross margin.

InfraREIT, Inc. (REIT) (NYSE:HIFR) is worth US$1.29 Billion and has recently fallen 0% to US$21. The latest exchange of 0.18 Million shares is below its average trading activity of 199.47 Million shares. The day began at US$21.11 but the price moved to US$21.11 at one point during the trading and finally capitulating to a session high of US$21.33. The stock tapped a 52-week high of US$23.22 while the mean 12-month price target for the shares is US$20.5.

Currently, the stock carries a price to earnings ratio of 53.44, a price to book ratio of 1.39, and a price to sales ratio of 6.55. For the past 5 years, the company’s revenue has grown 34.8%, while the company’s earnings per share has grown 0.3%. With an institutional ownership near 0%, it carries an earnings per share ratio of 0.39.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 3 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.75.